Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops - ARK Genomic Revolution ETF (BATS:ARKG), ARK Innovation ETF (BATS:ARKK)

Core Insights - CRISPR Therapeutics AG is facing renewed pressure due to insider sales, slow revenue growth, and weak product adoption [1] - The company's Momentum score has significantly declined, indicating a drop in investor confidence [2] Revenue Performance - The company's revenue for the third quarter was reported at $890,000, which is substantially below the consensus estimate of $8.06 million [4] - This disappointing revenue performance has contributed to a loss of confidence among investors [4] Insider Activity - CEO Samarth Kulkarni sold over 90,000 shares in a pre-arranged transaction, which has raised concerns among investors despite him retaining approximately 85,000 shares [3] - The timing and scale of these sales have unsettled the market, further impacting the stock's performance [3] Stock Performance - CRISPR Therapeutics AG's stock has dropped over 10% in the past week, leading to a decline in its Momentum score from 76.81 to 50.97 [2] - The stock is currently ranked poorly in Benzinga's Edge Stock Rankings, reflecting unfavorable price trends in both the short and medium terms [4]